InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Tuesday, 10/10/2017 12:21:49 PM

Tuesday, October 10, 2017 12:21:49 PM

Post# of 807
CTL019 has robust activity in DLBCL and triple-refractory Follicular Lymphoma and promising efficacy in Myeloma.